News & Updates

Honoring the memory of Jonas Salk, polio vaccine inventor, on his 106th birthday anniversary, during the COVID-19 pandemic

11/05/2020

Excerpt from the Article: LA JOLLA—As people across the world anxiously await the promise of an effective vaccine to end the coronavirus pandemic that has killed over 220,000 Americans and more than 1.1 million globally, it is important to remember a time when the world faced similar challenges and, through scientific research, found answers that…

Read More

Everything you need to know about SR&ED

11/04/2020

For our Canadian clients! “Learn about the SR&ED Program and how it benefits health science companies. OBIO will have experts from the CRA to explain the eligibility criteria, what expenditures qualify, and how to file a scientific research and experimental development (SR&ED) claim for this year.” To Register Click the Button Below: Register Free!

Read More

Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score™

11/04/2020

Excerpt from the Press Release: OCEANSIDE, Calif., Oct. 29, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today publication on the NIH clinical trials website1 of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk.  The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers,…

Read More

Register for our upcoming “Ask Us Anything In Clinical Research – Medical Device and Diagnostic Studies” virtual networking meeting!

11/03/2020

We are absolutely delighted with the positive engagement we’ve had from our first four Ask Us Anything in Clinical Research – Virtual Networking Meetings. It’s hard to believe we have had this many so far! Based on this success, we have decided to continue the series into 2021 with our next virtual meeting on November…

Read More

How scientists launched a study in days to probe COVID-19’s unpredictability

11/03/2020

Excerpt from the Article: On a Friday afternoon in mid-March 2020, as the emergency department at Massachusetts General Hospital began admitting its first coronavirus patients, attending emergency physician and researcher Michael Filbin recognized an urgent need to quickly learn about the emerging pathogen. With a surge of COVID-19 patients expected in the hospital in the…

Read More

IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study

11/02/2020

Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable…

Read More

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

11/01/2020

Excerpt from the Article: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further…

Read More

World first: focused ultrasound opens blood-brain barrier for delivery of therapeutic in Parkinson’s disease

10/31/2020

Excerpt from the Article: In a groundbreaking, world-first clinical trial, a team of researchers from Sunnybrook Health Sciences Centre and University Health Network are using focused ultrasound technology to deliver a therapeutic directly to affected brain regions in patients with Parkinson’s disease (PD). Parkinson’s affects more than 6 million people around the world. It is…

Read More

IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical Trial

10/30/2020

Excerpt from the Press Release: SAN CARLOS, Calif., Oct. 20, 2020 /PRNewswire/ — IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer’s FDA-approved CCR5 antagonist Maraviroc.  The trial “Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2″seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for…

Read More

Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19 Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States

10/29/2020

Excerpt from the Press Release: BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX:…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives